Please Wait...

Klause Engelke

Translation skills

Main profile

Klaus Engelke, PhD.
Director of Special Imaging Techniques

Professor Klaus Engelke received a Ph.D. in Physics from the University of Hamburg, Germany for his pioneering work on µCT using Synchrotron Radiation. Afterwards he joined the Osteoporosis Research Group at UCSF (University of California at San Francisco) to develop advanced radiographic methods for the diagnosis of osteoporosis. At UCSF he also developed the first workstation for vertebral fracture analysis using digitized x-rays. He then joined the newly formed Institute of Medical Physics (IMP) at the University of Erlangen, Germany to develop desktop µCT Scanners and advanced image processing methods. Prof. Engelke joined Synarc, now Bioclinica, as a Director of Special Imaging Techniques in 2005. At the University of Erlangen he continues to develop novel in vivo and in vitro image acquisition and analysis techniques for the musculoskeletal field. He has authored more than 100 peer reviewed publications and more than 200 conference contributions. In 2007 he chaired the QCT Task Force that developed the official positions of the International Society of Clinical Densitometry (ISCD) and is member of the committee that developed the German guidelines for the diagnosis and treatment of osteoporosis. In 2017 he was awarded the Dr. John P. Bilezikian Global Leadership Award from the International Society for Clinical Densitometry, which recognizes Klaus for his contributions to the advancement of osteoporosis and bone imaging research. He is also a member of the scientific advisory committee of the International Osteoporosis Foundation and co-chaired the Committee on Bone Densitometry of the International Commission on Radiation Units (ICRU).

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

Read our CEO’s thoughts on Bioclinica’s mission-driven growth agenda. https://t.co/d3OGmHAhK0 #bioclinica… https://t.co/0c2iqAAol6
Bioclinica (22 hours ago)
Changes are a fact of life - and of #clinicaltrial design. But that doesn't mean planning and budgeting for your tr… https://t.co/BUPFjuIXOt
Bioclinica (3 days ago)
Bioclinica announced today that the company has contributed data to the primary efficacy endpoint in more than 200… https://t.co/8epFHqKFcL
Bioclinica (2 weeks ago)
No change order fees for new clients with our #RTSM platform means fewer hurdles as you race to study start. Ready… https://t.co/Z5AOtkWT3e
Bioclinica (2 weeks ago)
With over 25 years of experience in Cardiac Safety monitoring services, Bioclinica is a recognized global leader in… https://t.co/CMY48C4QVR
Bioclinica (3 weeks ago)
Bioclinica is an agile organization with more 2,300 colleagues around the globe - and growing! Learn more here.… https://t.co/oLPRURkhm7
Bioclinica (3 weeks ago)